Brind.

Alpha Tau Medical Ltd. announced on September 2, 2025, that it has initiated a multi-center clinical trial in the United States.

Steady: 0 in the last 7 days Updated oct 22

The latest in this situation

  1. Alpha Tau expands its clinical trial scope with SMC and plans a six-country program.

How it started

3 reports, 2 independent, last reported Oct 22. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Alpha Tau Medical Ltd. announced on September 2, 2025, that it has initiated a multi-center clinical trial in the United States.

How it developed

Newest first. Tap a step to see who reported it.
  1. Alpha Tau expands its clinical trial scope with SMC and plans a six-country program.1 source
  2. Alpha Tau Medical Ltd. developed the Alpha DaRT therapy for solid tumors, leveraging technology from Tel Aviv University.Sub-event
  3. Alpha Tau Medical Ltd. announced on September 2, 2025, that it has initiated a multi-center clinical trial in the United States.1 source
  4. FDA granted IDE approval for Alpha Tau's pilot study; Alpha Tau also secured funding from Oramed.1 source

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GlobeNewswireAlpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial – First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U
  • GlobeNewswireAlpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update - FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent